Endocrine Abstracts

Hepatic effects of I131 administration in endocrine disorders are not mentioned in drug’s recipe and are rarely described in medical literature. We present the case of a 32 years old woman who was admitted and investigated for myalgias, arthralgias, asthenia and elevated transaminases (ALAT=482.22 UI/l). The patient was diagnosed in 2022 with autoimmune thyroiditis and a dominant nodule (TIRADS 4) in the right lobe. Thyroidectomy was performed in 2023 and multifocal, partially incapsulated papillary carcinoma was detected. Three months after thyroidectomy, a dosage of 30 mCi of I131 was administered. Five months after thyroidectomy, the patient was admitted for the previous symptoms. After multiple and extensive investigations, using the Roussel Uclaf Causality Assessment Method scaler, the diagnosis of drug (I131) induced liver injury was considered. After conventional hepatoprotective treatment failed to improve patient’s status, corticoid treatment was used, with a benefic outcome. Even if liver injury is not cited as an adverse effect of I131 administration, it must be taken into consideration. The manifestations start after a long time (3-6 weeks) post-exposure and they do not respond to conventional hepatoprotective treatment but to corticotherapy.